Ashkon Software

   







 


CVM Stock Report - CEL-SCI Corp.

CEL-SCI Corp. logo CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 product candidates for the treatment of rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

 



Stock Sector: Drugs: Biotechnology


 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer